Overexpression of G-Protein-Coupled Receptor 40 Enhances the Mitogenic Response to Epoxyeicosatrienoic Acids

Seong Kwon Ma¹², Yinqiu Wang¹, Jianchun Chen¹, Ming-Zhi Zhang¹, Raymond C. Harris¹*, Jian-Kang Chen³

¹ Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, ² Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea, ³ Departments of Cellular Biology & Anatomy and Medicine, Medical College of Georgia, Georgia Regents University, Augusta, Georgia, United States of America

* ray.harris@vanderbilt.edu

Abstract

The cytochrome P450 epoxygenase-dependent arachidonic acid metabolites, epoxyeicosatrienoic acids (EETs), are potent survival factors and mitogens for renal epithelial cells, but the molecular identity in the cells that initiates the mitogenic signaling of EETs has remained elusive. We screened kidney cell lines for the expression of G-protein-coupled receptor 40 (GPR40) and found that the porcine renal tubular epithelial cell line LLCPKcl4, which has been previously demonstrated to be sensitive to the mitogenic effect of EETs, expresses higher levels of GPR40 mRNA and protein than the human embryonic kidney cell line HEK293. EETs induced only a weak mitogenic EGFR signaling and mild cell proliferation in HEK293 cells. To determine whether GPR40 expression level is what mediates the mitogenic sensitivity of cells to EETs, we created a human GPR40 (hGPR40) cDNA construct and transfected it into HEK293 cells and picked up a number of stable transfectants. We found that GPR40 overexpression in HEK293 cells indeed significantly enhanced EET-induced cell proliferation and markedly augmented EGFR phosphorylation ERK activation, which were inhibited by the EGFR tyrosine kinase inhibitor, AG1478, or the HB-EGF inhibitor, CRM197. EETs significantly enhanced release of soluble HB-EGF, a natural ligand of EGFR, into the culture medium of hGPR40-transfected HEK293 cells, compared to empty vector-transfected cells. In mouse kidneys, markedly higher level of GPR40 protein was found in the cortex and outer stripe of outer medulla compared to the inner stripe of outer medulla and inner medulla. In situ hybridization confirmed that GPR40 mRNA was localized to a subset of renal tubules in the kidney, including the cortical collecting duct. Thus, this study provides the first demonstration that upregulation of GPR40 expression enhances the mitogenic response to EETs and a relatively high expression level of GPR40 is detected in a subset of tubules including cortical collecting ducts in the mammalian kidney.
Introduction

Arachidonic acid is a polyunsaturated 20 carbon omega-6 fatty acid that is an important constituent of cellular membranes. It is normally esterified to the sn-2 position of glycerophospholipids and is released from selected lipid stores following activation of specific phospholipases [1]. Metabolism of released arachidonic acid by the cytochrome P450-dependent monoxygenase pathway produces biologically active compounds in two ways: epoxidation, producing 5,6-, 8,9-, 11,12-, 14,15-epoxyeicosatrienoic acids (EETs) and ω/-ω-1 hydroxylation, resulting in the formation of 19- and 20-hydroxyeicosatetraenoic acids (HETEs) [2–4]. EETs have been demonstrated to play important roles in regulating vascular tone, platelet aggregation, tissue and body homeostasis, Ca2+ signaling and steroidogenesis [3–9]. In addition, EETs have been suggested to be an endothelium-derived hyperpolarizing factor in vasculature [10,11].

EETs are synthesized primarily by epoxygenases of the 2C gene subfamily of cytochrome P450 enzymes (Cyp2c) that are highly expressed in the mammalian kidney. Our previous studies indicate that EETs promote renal epithelial cell survival by activation of a PI3K-Akt signaling pathway [15]. We also reported that EETs stimulate proliferation of cultured renal epithelial cells and elucidated underlying intracellular signaling pathways [12–14, 16]. More recent studies have demonstrated that Cyp2c44 epoxygenase is responsible for the production of EETs that activate ERK1/2 to phosphorylate and inhibit the γ subunit of the epithelial sodium channel (ENaC) in the kidney; therefore, knocking out Cyp2c44 epoxygenase causes dietary salt-sensitive hypertension [17]. However, these prior studies did not pinpoint the site that EETs act upon to initiate the intracellular signaling cascades and did not identify a functional receptor for EETs.

G-protein-coupled receptor 40 (GPR40) was first described as an orphan 7-transmembrane G protein-coupled receptor in 1997 [18]. Subsequent studies identified medium- and long-chain fatty acids as its putative ligands even at physiologically relevant concentrations. Accordingly, the receptor is now also known as free fatty acid receptor 1 (FFAR1), the first identified member of a family of FFARs that also includes GPR41, GPR43, GPR119 and GPR120 [19]. Of note, GPR40 is most highly expressed in brain and pancreatic islets, leading to the suggestion that GPR40 is involved in the regulation of insulin secretion in response to free fatty acids [20,21]. Interestingly, subsequent studies increasingly indicate that GPR40 is also expressed in other organs [20–22]. To date, however, no previous studies have investigated the expression and function of GPR40 in the mammalian kidney.

Here we show that during a screening for GPR40 expression in kidney cell lines, we found that the porcine renal tubular epithelial cell line LLCPKc14, which is sensitive to EETs and has been utilized to identify the biological effects and the underlying molecular signaling mechanism of EETs [12–16], expresses a markedly higher level of GPR40 than the human embryonic kidney cell line HEK293, which we confirmed is not sensitive to the mitogenic response to EETs. We therefore created a human GPR40 (hGPR40) cDNA construct and transfected it into the HEK293 cells and established several stable clones expressing hGPR40 to test whether the sensitivity of cells to the mitogenic signaling and biological response to EETs is mediated by GPR40. We also examined the expression pattern of GPR40 in mammalian kidney. Our results suggest that upregulation of GPR40 expression enhances the release of soluble HB-EGF, which serves as a natural ligand to transactivate EGF receptor and downstream ERK phosphorylation and biological effects of EETs. We also determined that even under the normal physiological condition, GPR40 is indeed expressed in the nephron segments of the mammalian kidneys, including branching cortical collecting ducts.
Results

In initial studies, we screened kidney epithelial cell lines for GPR40 expression, and found that the porcine renal tubular epithelial cell line LLCPKc14 expressed markedly higher levels of GPR40 mRNA and protein while the human embryonic kidney cell line HEK293 had a very low level of GPR40 expression (Fig. 1) and confirmed that HEK293 cells are not sensitive to the mitogenic effect of EETs. Previous studies revealed that LLCPKc14 cells are sensitive to the mitogenic effect of EETs and have been utilized to identify the tyrosine kinase phosphorylation cascade activated by EETs [12–16]. To test whether increasing the expression level of GPR40 in the HEK293 cells could increase their sensitivity to the mitogenic effect of EETs, we designed a pair primer specific for hGPR40 cDNA and generated a human GPR40 (hGPR40) cDNA construct utilizing the mammalian expression vector, pcDNA3.1/V5-His-TOPO vector as detailed in Methods. We then transfected the hGPR40 cDNA construct into HEK293 cells and developed a number of HEK293 cell clones stably expressing human GPR40 (Fig. 2A). The stable HEK293 clones overexpressing hGPR40 showed markedly increased ERK phosphorylation in response to 11,12-EET and 14,15-EET in a concentration-dependent manner. Shown in Fig. 2B are representative results from clone-5. These experiments were repeated in at least two of these stable clones with similar results. Importantly, 14,15-EET-stimulated cell proliferation was significantly augmented in these hGPR40-overexpressing stable clones, compared to the empty vector-transfected HEK293 cells, which showed a small but significant increase in cell number in response to 14, 15-EET stimulation (Fig. 3), consistent with the low basal expression level of GPR40 protein in non-transfected HEK293 cells (Fig. 1A).

Previous studies demonstrated that EET-dependent cell proliferation in porcine renal tubular epithelial cells is mediated by EGFR transactivation and ERK activation [16]. In the present study, we observed minimal EGFR and ERK phosphorylation in response to 14,15-EET in empty vector-transfected HEK293 cells (Fig. 4), consistent with the minimal expression of GPR40 protein in the non-transfected HEK293 cells (Fig. 1A). In contrast, 14,15-EET-induced phosphorylation of both EGFR and ERK were markedly augmented in GPR40-transfected HEK293 cells (Fig. 4). To confirm that the observed increases in ERK phosphorylation were mediated by EGFR activation, we pretreated the cells with the EGFR tyrosine kinase inhibitor, AG1478, and found that the EET-induced ERK phosphorylation was markedly inhibited by AG1478 inhibition of EGFR phosphorylation (Fig. 5A). Previous studies demonstrated that EET-stimulated EGFR transactivation was mediated by cleavage of membrane-bound HB-EGF and release of soluble HB-EGF (sHB-EGF), a natural ligand for EGFR [16]. Accordingly, we pretreated the GPR40-overexpressing cells with the HB-EGF inhibitor, CRM197. As indicated in Fig. 5B, CRM197 pretreatment inhibited the EET-induced increases in EGFR and ERK phosphorylation. Furthermore, we also measured sHB-EGF in the culture medium of HEK293 cells in response to 14,15-EET administration and detected significantly more sHB-EGF release into the culture medium of GPR40-overexpressing HEK293 cells in response to EET stimulation (Fig. 6). These data suggest that increasing GPR40 expression indeed enhanced the sensitivity of HEK293 cells to the mitogenic stimulation of EETs by augmenting sHB-EGF release and EGFR transactivation-dependent ERK phosphorylation.

In addition to cultured renal epithelial cells, we determined that GPR40 mRNA is indeed expressed in mouse kidney (Fig. 7). Immunoblotting indicated that the protein expression levels of GPR40 were higher in cortex and OSOM than ISOM and inner medulla (Fig. 7C). In situ hybridization revealed that GPR40 mRNA was localized to a subset of renal tubules in the kidney cortex, including the collecting duct (Fig. 8).
Discussion

EETs are produced predominantly by epoxygenases of the 2C gene subfamily of cytochrome P450s in the mammalian kidney [25–29]. Utilizing the EET-sensitive porcine renal epithelial cell line LLCPKcl4, we have previously demonstrated that EETs stimulates cell proliferation by releasing the natural EGFR ligand, sHB-EGF and thus activating EGFR-dependent ERK signaling pathway [12–16]. The present studies indicate that the medium- and long-chain fatty acid receptor GPR40 is expressed in renal epithelia of the mammalian kidney and this EET-sensitive
Fig 2. (A) The protein expression of human GPR40 (hGPR40) in the HEK293 cells transfected with human GPR40 cDNA construct. An anti-human GPR40 antibody was used for immunoblotting. Shown are representative stable clones expressing different levels of human GPR40. NT, non-transfected HEK293 cells, used as a negative control. (B) Quiescent hGPR40-transfected HEK293 cells were exposed to different concentrations of 11,12-EET or 14,15-EET for 15 min. 11,12-EET and 14,15-EET concentration-dependently induced ERK1/2 phosphorylation, respectively, in hGPR40-transfected HEK293 cells, compared with vehicle. The same immunoblot was stripped and re-probed with total ERK antibodies to ensure equal loading and transfer. Shown are representative blots of 3 separate experiments with similar results. *p<0.05 compared with vehicle alone in hGPR40 transfected HEK293 cells.

doi:10.1371/journal.pone.0113130.g002
LLCPKcl4 cell line expresses a relatively higher level of GPR40 than the HEK293 cell line. By increasing GPR40 expression in HEK293 cells, we were able to sensitize HEK293 cells to the mitogenic signaling and biological effect of EETs. Specifically, in the presence of upregulated GPR40 expression in cultured renal epithelial cells, EET induces EGFR activation and downstream signaling by releasing soluble HB-EGF, which is a natural ligand for EGF receptor. The released HB-EGF binds to EGFR and activates its intrinsic receptor tyrosine kinase and subsequent ERK activation. These data also provide evidence that inhibiting activity of soluble HB-EGF or blocking the intrinsic EGFR tyrosine kinase is each sufficient to inhibit GPR40-mediated intracellular signaling initiated by EETs.

A previous study indicated that the fatty acid, oleic acid, activated EGFR signaling in breast cancer cells. Oleic acid can serve as a ligand for GPR40, as well as the related fatty acid receptor GPR120, and MCF-7 cells, the cell type used in the studies, expressed both receptors [30]. However, the studies did not directly test whether GPR40 activation was necessary for the EGFR activation in these cells. Since its deorphanization and identification as a receptor for medium- and long-chain fatty acids in 2003, there has been increasing interest in defining the potential physiologic roles of GPR40 [20]. The majority of attention has been directed at possible roles in regulation of insulin secretion. In this regard, GPR40 agonists have been developed as possible agents to stimulate insulin secretion in type 2 diabetes [31–33]. GPR40 is also expressed in enteroendocrine cells of gastrointestinal tract, and may mediate release of glucagon-like peptide-1 and cholecystokinin secretion [34,35]. In addition, GPR40 is expressed in murine skin and may serve to limit and attenuate inflammation [36]. Recent studies have also
implicated GPR40 in regulation of pain perception [37]. Finally, GPR40, along with another fatty acid receptor, GPR120, has been implicated in sensing taste of fatty acids [38]. However, renal expression and function of GPR40 have not yet been investigated. In the present study, we demonstrated that overexpression of GPR40 enhances mitogenic signaling of EETs, cytochrome P450 epoxygenase metabolites of the 20-carbon fatty acid, arachidonic acid. We have also determined that a relatively high expression level of GPR40 is detected in a subset of kidney tubules, including the cortical collecting duct, the nephron segment that can branch, in the mammalian kidney. Expression of GPR40 in cortical collecting duct (CCD) is of interest because recent studies indicate that a potential physiologic role for EETs is to modulate sodium reabsorption in this nephron segment by inhibiting epithelial sodium channel (ENaC) open probability [28]. Furthermore, previous studies demonstrated that EGFR activation inhibited CCD sodium reabsorption [39,40]. Our recent study also indicated a role for EGFR activation in EET-mediated ENaC inhibition [41]. Given the identification of GPR40 expression in CCD in the current studies, it is interesting to speculate that it may play a role in modulation of ENaC activity and sodium reabsorption, but further studies will be necessary to determine physiologic roles of GPR40 in mammalian kidney.

In summary, our studies revealed that EETs can induce mitogenic signaling by inducing EGFR transactivation through release of the EGFR ligand, HB-EGF in a GPR40-dependent manner. We further demonstrated that GPR40 is expressed in renal epithelia in vivo. However, additional experiments are required to determine whether GPR40 serves as a receptor to mediate the biologic effects of EETs.
Materials and Methods

Reagents and antibodies

Anti-EGFR and anti-phospho-EGFR antibodies were purchased from Cell Signaling Technology (Beverly, MA). Anti-ERK and anti-phospho-ERK antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). An antibody specific to heparin-binding epidermal growth factor-like growth factor (HB-EGF) was from R&D Systems (Minneapolis, MN). Anti-GPR40 antibodies were obtained from Epitomics (Burlingame, CA) and Santa Cruz Biotechnology (Santa Cruz, CA). Fluorescein Lotus tetragonolobus agglutinin (LTA) was from Vector Laboratories (Burlingame, CA). Anti-aquaporin-2 (AQP2) antibody was from Abcam (Cambridge, MA). Anti-Tamm-Horsfall protein (THP) antibody was from AbD Serotec (Raleigh, NC). Anti-calbindin-D28K antibody was from Sigma-Aldrich (St. Louis, MO). EETs were a
Fig 6. Overexpression of human GPR40 in HEK293 cells enhanced release of soluble HB-EGF into conditioned media. Empty vector-transfected HEK293 cells (Vector) and human GPR40-transfected HEK293 cells (hGPR40) were rendered quiescent in serum-free medium and washed twice with PBS, followed by treatment with vehicle or 14,15-EET, respectively. The conditioned media were applied to a heparin-Sepharose column to purify heparin-binding proteins as described in Experimental Procedures and analyzed by immunoblotting with an antibody specific for HB-EGF. Shown is a representative blot from three separate experiments with similar results and the densitometry quantification of released soluble HB-EGF from the three experiments.

doi:10.1371/journal.pone.0113130.g006
A generous gift from Jorge Capdevila (Vanderbilt University). Heparin-Sepharose CL-6B column was from Amersham Pharmacia Biotech (Piscataway, NJ). AG1478 was purchased from Calbiochem (San Diego, CA). CRM197 and all other chemicals were from Sigma-Aldrich (St. Louis, MO).

**Cell culture**

The human embryonic kidney cell line HEK293 (ATCC), the African green monkey kidney cell line COS-7 (ATCC), and the porcine renal tubular epithelial cell line LLCPK14 (obtained from Lee Limbird; originally developed by Kurt Amsler) were routinely cultured in Dulbecco’s

**Fig 7. GPR40 expression in murine kidney.** (A) In addition to pancreas and brain (used as positive controls), kidneys also express GPR40 in the mouse, revealed by similar immunoblotting analysis. B) RT-PCR indicated GPR40 mRNA was expressed in mouse kidneys. C) Immunoblotting revealed that the levels of GPR40 protein were higher in the cortex and outer stripe of outer medulla (OSOM) than in inner stripe of outer medulla (ISOM) and inner medulla (IM). Similar results were obtained using two antibodies: one from Epitomics (Burlingame, CA) and another from Santa Cruz Biotechnology (Santa Cruz, CA). Both were rabbit antibodies raised against GPR40 of human origin but according to manufacturer’s data sheets, both antibodies are recommended for the detection of GPR40 of human, mouse, and rat origins. Shown in (A) and (C) are representative immunoblots resulted from the GPR40 antibody from Epitomics.

doi:10.1371/journal.pone.0113130.g007
modified Eagle’s medium (DMEM)/F-12 mixture supplemented with 10% fetal bovine serum (FBS) at 37°C in a 5% CO2 cell culture incubator. The medium was changed every 2 to 3 days.

Animal Care and Usage

Animals were housed at the Vanderbilt veterinary facility. Animal care and all experimental protocols in our studies were approved by the Vanderbilt University Institutional Animal Use and Care Committee, and all experiments were conducted according to the regulations of Vanderbilt University’s Institutional Animal Care and Usage Committee and complied with the guidelines of National Institutes of Health. Eight weeks old male Balb/c mice from The Jackson Laboratory (Bar Harbor, ME) were euthanized and their kidneys, pancreas, and brains were harvested to determine the expression of GPR40.

RT-PCR

Total RNA was extracted by using TRI-reagent (Molecular Research Center, Cincinnati, OH) and chloroform extraction [12]. Three micrograms of total RNA was used for reverse-transcription utilizing the First Strand cDNA Synthesis Kit from Amersham Pharmacia Biotech (Piscataway, NJ). The resultant first-strand cDNA was then amplified using primer pairs specific for GPR40 in a GeneAMP 9600 PCR System using Taq polymerase (PerkinElmer/Cetus, Boston, MA). PCR was performed for 30 cycles at 95°C for 45 s, 65°C for 45 s, and 72°C for 60 s followed by a 7 min extension at 72°C. The primer pairs used for the amplification of porcine GPR40 from LLCPKcl4 cells are: 5’-GCT GCT CTG ACC TCC TGC TGG-3’ (forward) and 5’-TAG CTT CCG TCT GTG GCT CAG G-3’ (reverse). For amplification of human GPR40 from HEK293 cells, we used 5’-ATG GAC CTG CCC CCG CAG CTC-3’ (forward primer) and 5’-TTG CTT CCG TCT GCT TGT GCT CAG G-3’ (reverse primer).

Construction of human GPR40 expression vector

To stably transfet human GPR40 cDNA into HEK293 cells, the cDNA containing the entire coding region of human GPR40 was amplified with a synthetic primer pair (Sense: GCC ACC ATG GAC CTG CCC CCG CAG CTC and antisense: CTT CTG GGA CTT GCC CCC TTG
CGT TC) utilizing high-fidelity-Taq PCR with a cDNA clone containing the full length of human GPR40 (FFAR1) cDNA as template (Thermo Scientific Open Biosystems, Huntsville, AL). The amplification product was purified and subcloned into the mammalian expression vector, pcDNA3.1/V5-His-TOPO vector (Invitrogen, Carlsbad, CA). The expected sense orientation to the human cytomegalovirus (CMV) promoter in the expression vector was identified by restriction enzyme digestion analysis, and the correct sequence of human GPR40 cDNA construct was further confirmed by sequencing analysis.

Transfection

Stable transfection of the human GPR40 cDNA construct or empty vector alone (used as a control) into HEK293 cells, respectively, and selection of stable transfectants expressing human GPR40 were conducted as described previously [13].

Cell proliferation

The assay was performed as we have previously described [12,13]. Briefly, a total of 1.5 × 10^5 HEK293 cells per well were seeded into 24-well plates. After 24 h of growth in DMEM/F-12 mixture containing 10% FBS, the medium was changed to serum-free medium and incubated for an additional 48 h to make the cells quiescent. Cells were then exposed to 5 μM EET or vehicle alone in the presence of 0.5% FBS in the medium. Cell number per well in each treatment group was counted every day. Results were plotted as the cell number/well for the indicated durations. Each experimental data point represents triplicate wells from three different experiments.

Immunoblotting

For in vitro experiments, cells were made quiescent in serum free medium for 48 hours before treatment of the cells with the indicated reagents. The cells were then washed twice with ice-cold Ca^{2+}/Mg^{2+}-free phosphate-buffered saline (PBS) and lysed on ice for 30 min with RIPA buffer [12]. For in vivo experiments, the renal cortex along with the outer strip of outer medulla (OSOM) were dissected and the inner stripe of outer medulla (ISOM) along with the inner medulla of mouse kidneys were homogenized in RIPA buffer. Lysates were clarified by centrifugation at 10,000 × g for 15 min at 4°C, and protein concentrations were determined. The lysates were subjected to 7.5–15% sodium dodecyl sulfate (SDS)-polyacrylamide gels, transferred onto PVDF membranes, probed with the indicated primary antibody and the appropriate secondary antibody conjugated with biotin, incubated with preformed avidin-biotin-horseradish peroxidase complex using a commercially available kit (Vectastatin ABC kit, Vector laboratories, Burlingame, CA), and detected by a peroxidase-catalyzed enhanced chemiluminescence detection system (PerkinElmer, Boston, MA).

Purification of secreted HB-EGF

Secreted soluble HB-EGF (sHB-EGF) was purified by a modification of previously described heparin affinity chromatography [23]. Briefly, before exposure to vehicle or the indicated agents in serum-free media, confluent cells were rendered quiescent and washed twice with PBS. Conditioned media (CM) were centrifuged and filtered through a 0.45-mm filter. Each sample of CM was immediately applied to a heparin-sepharose column which was preequilibrated with 10 mM Tris-HCl (pH 7.4) containing 0.2 M NaCl and 1 mM benzamidine. After extensive washing with equilibration buffer, bound proteins were eluted with 2.0 M NaCl in 10 mM Tris-HCl (pH 7.4) and dialyzed against 10 mM Tris-HCl (pH 7.4) at 4°C overnight. The dialyzed effluent was
lyophilized, then resuspended and boiled in protein sample buffer before separation on 18% SDS-polyacrylamide gels, followed by immunoblotting with an anti-HB-EGF antibody [16].

In situ hybridization
In situ hybridization was performed with digoxigenin-labeled nucleic acid probes as described previously with some modifications [24]. Briefly, the mouse GPR40 gene antisense probe was labeled with DIG RNA labeling kit (Roche Applied Science, Mannheim, Germany) and the sense probe was synthesized at the same time as a control. Mouse kidneys were fixed in 4% paraformaldehyde, then processed to 10 μm paraffin sections. Paraffin slides were fixed in 4% paraformaldehyde for 10 min, deparaffinized and deproteinized with protease K for 15 min. Slides were then fixed again with 4% paraformaldehyde for 5 min. After washing with PBS, slides were acetylated for 10 min, and permeabilized with 1% Triton X-100 for 20 min. After washing with PBS, pre-hybridization was carried out at 55°C for 2 h. Subsequently, slides were incubated in hybridization buffer with probes at 55°C overnight and then washed with 0.2X SSC for 2 h, then Tris-Saline buffer for 5 min, followed by blocking with 10% heat inactivated sheep serum for 2 h. The probe-target complex was detected immunologically by a digoxigenin antibody conjugated to alkaline phosphatase acting on nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP, Roche Applied Science, Mannheim, Germany) according to the manufacturer’s protocol. Slides were examined under a light microscope.

Statistics
Data are presented as means ± SEM for at least three separate experiments (each in triplicate or duplicate). An unpaired Student’s t-test was used for statistical analysis. For multiple group comparisons, ANOVA and Bonferroni t-test were used. A P value of <0.05 compared with control was considered statistically significant.

Conclusion
Upregulation of GPR40 enhances the mitogenic response to EETs, and a relatively high expression level of GPR40 occurs selectively in a subset of renal tubules including cortical collecting ducts in the mammalian kidney. However, future studies are required to determine whether GPR40 serves as a functional receptor for EETs to mediate EETs’ biologic effects.

Author Contributions
Conceived and designed the experiments: RCH J-KC. Performed the experiments: SKM YW JC. Analyzed the data: JC M-ZZ RCH J-KC. Wrote the paper: SKM RCH J-KC.

References
1. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB (1986) Arachidonic acid metabolism. Annu Rev Biochem. 55, 69–102. PMID: 3017195
2. Samuelsson B, Dahlén SE, Lindgren JA, Rouzer CA, Serhan CN (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 237, 1171–6. PMID: 2820055
3. Makita K, Falck JR, Capdevila JH (1996) Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for an old enzyme system. FASEB J. 10, 1456–63. PMID: 8940291
4. Rahman M, Wright JT Jr, Douglas JG (1997) The role of the cytochrome P450-dependent metabolites of arachidonic acid in blood pressure regulation and renal function: a review. Am J Hypertens. 10, 356–65. PMID: 9056695
5. Harder DR, Campbell WB, Roman RJ (1995) Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J Vasc Res. 32, 79–92. PMID: 7537544
6. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, Spector AA (1997) Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res. 81, 258–67. PMID: 9242187

7. Fitzpatrick FA, Ennis MD, Baze ME, Wynalda MA, McGee JE, et al. (1986) Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem. 261, 15334–8. PMID: 3095326

8. Graber MN, Alfonso A, Gill DL (1997) Recovery of Ca2+ pools and growth in Ca2+ pool-depleted cells is mediated by specific epoxyeicosatrienoic acids derived from arachidonic acid. J Biol Chem. 272, 29546–53. PMID: 9368016

9. Medhora M, Harder D (1998) Functional role of epoxyeicosatrienoic acids and their production in astrocytes: approaches for gene transfer and therapy (review). Int J Mol Med. 2, 661–9. PMID: 9850733

10. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 78, 415–23. PMID: 8593700

11. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, et al. (1999) Cytochrome P450 2C is an EDHF dothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res. 81, 258

12. Chen JK, Falck JR, Reddy KM, Capdevila J, Harris RC. (1998) Epoxyeicosatrienoic acids and their sulfonamide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells. J Biol Chem. 273, 29254–61. PMID: 9766938

13. Chen JK, Wang DW, Falck JR, Capdevila J, Harris RC. (1999) Transfection of an active cytochrome P450 arachidonic acid epoxygenase indicates that 14,15-epoxyeicosatrienoic acid functions as an intracellular second messenger in response to epidermal growth factor. J Biol Chem. 274, 4764–9. PMID: 9987114

14. Chen JK, Capdevila J, Harris RC. (2000) Overexpression of C-terminal Src kinase blocks 14, 15-epoxyeicosatrienoic acid-induced tyrosine phosphorylation and mitogenesis. J Biol Chem. 275, 13789–92. PMID: 10788500

15. Chen JK, Capdevila J, Harris RC. (2001) Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol. 21, 6322–31. PMID: 11509673

16. Chen JK, Capdevila J, Harris RC. (2002) Heparin-binding EGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cell. Proc Natl Acad Sci U S A. 99, 6029–34. PMID: 11983897

17. Capdevila JH, Pidkovka N, Mei S, Gong Y, Falck JR, et al. (2014) The Cyp2c44 epoxygenase regulates expression changes in the brain. Methods Mol Biol. 670, 207. PMID: 9344866

18. Costanzi S, Neumann S, Gershengorn MC. (2008) Seven transmembrane-spanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects. J Biol Chem. 283, 16269–73. doi: 10.1074/jbc.M108.694055 PMID: 18385136

19. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, et al. (2003) The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem. 278, 13909–14. doi: 10.1074/jbc.M113.508416 PMID: 13985476

20. Sawaedzargo M, George SR, Nguyen T, Xu S, Kolakowski LF, et al. (1997) A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. Biochim Biophys Res Commun. 239, 543–7. PMID: 9344866

21. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujiy R, et al. (2003) Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 422, 173–6. PMID: 12629551

22. Gras D, Chanez P, Urbach V, Vachier I, Godard P, et al. (2009) Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor. Am J Physiol Lung Cell Mol Physiol. 296, L970–8. doi: 10.1152/ajplung.90219.2008 PMID: 19346435

23. Sakai M, Zhang M, Homma T, Garrick B, Abraham JA, et al. (1997) Production of heparin binding epidermal growth factor-like growth factor in the early phase of regeneration after acute renal injury. Isolation and localization of bioactive molecules. J Clin Invest. 99, 2128–38. PMID: 9151785

24. Palop JJ, Roberson ED, Cobos I. (2011) Step-by-step in situ hybridization method for localizing gene expression changes in the brain. Methods Mol Biol. 670, 207–30. doi: 10.1007/978-1-60761-744-0_15 PMID: 20967593

25. Morrison AR, Pascoe N. (1981) Metabolism of arachidonate through NADPH-dependent oxygenase of renal cortex. Proc Natl Acad Sci U S A. 78, 7375–8. PMID: 6801649

26. Endou H. (1983) Cytochrome P-450 monoxygenase system in the rabbit kidney: its intraneprhon localization and its induction. Jpn J Pharmacol. 33, 423–33. PMID: 6310191

27. Bums KD, Capdevila J, Wei S, Breyer MD, Homma T, et al. (1995) Role of cytochrome P-450 epoxygenase metabolites in EGF signaling in renal proximal tubule. Am J Physiol. 269, C831–40. PMID: 7485450
28. Wei Y, Lin DH, Kemp R, Yaddanapudi GS, Nasjletti A, et al. (2004) Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways. J Gen Physiol. 124, 719–27. PMID: 15545402

29. Roman RJ, Maier KG, Sun CW, Harder DR, Alonso-Galicia M. (2000) Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol. 27, 855–65. PMID: 11071299

30. Soto-Guzman A, Robledo T, Lopez-Perez M, Salazar EP. (2008) Oleic acid induces ERK1/2 activation and AP-1 DNA binding activity through a mechanism involving Src kinase and EGFR transactivation in breast cancer cells. Mol Cell Endocrinol. 294, 81–91. doi:10.1016/j.mce.2008.08.003 PMID: 18775472

31. Ou HY, Wu HT, Hung HC, Yang YC, Wu JS, et al. (2013) Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonist, in the regulation of glucose homeostasis and insulin sensitivity. Am J Physiol Endocrinol Metab. 304, E668–76. doi: 10.1152/ajpendo.00419.2012 PMID: 23341496

32. Burant CF. (2013) Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes. Diabetes Care. 36 Suppl 2, S175–9.

33. Poitout V, Lin DC. (2013) Modulating GPR40: therapeutic promise and potential in diabetes. Drug Discov Today. 18, 1301–8. doi: 10.1016/j.drudis.2013.09.003 PMID: 24051395

34. Edfalk S, Steneberg P, Edlund H. (2008) Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes. 57, 2280–7. doi: 10.2337/db08-0307 PMID: 18519800

35. Liou AP, Lu X, Sei Y, Zhao X, Pechhold S, et al. (2011) The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology. 140, 903–12. doi: 10.1053/j.gastro.2010.10.012 PMID: 20955703

36. Fujita T, Matsuoka T, Honda T, Kabashima K, Hirata T, et al. (2011) A GPR40 agonist GW9508 suppresses CCL5, CCL17, and CXCL10 induction in keratinocytes and attenuates cutaneous immune inflammation. J Invest Dermatol. 131, 1660–7. doi: 10.1038/jid.2011.123 PMID: 21593768

37. Nakamato K, Nishinaka T, Matsumoto K, Kasuya F, Mankura M, et al. (2012) Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system. Brain Res. 1432, 74–83. doi: 10.1016/j.brainres.2011.11.012 PMID: 22137657

38. Cartoni C, Yasumatsu K, Ohkuri T, Shigemura N, Yoshida R, et al. (2010) Taste preference for fatty acids is mediated by GPR40 and GPR120. J Neurosci. 30, 8376–82. doi: 10.1523/JNEUROSCI.0496-10.2010 PMID: 20573884

39. Vehaskari VM, Hering-Smith KS, Moskowitz DW, Weiner ID, Hamm LL. (1989) Effect of epidermal growth factor on sodium transport in the cortical collecting tubule. Am J Physiol. 256, F803–9. PMID: 2655477

40. Shen JP, Cotton CU. (2003) Epidermal growth factor inhibits amiloride-sensitive sodium absorption in renal collecting duct cells. Am J Physiol Renal Physiol. 284, F57–64. PMID: 12388407

41. Pidkova N, Rao R, Mei S, Gong Y, Harris RC, et al. (2013) Epoxyeicosatrienoic acids (EETs) regulate epithelial sodium channel activity by extracellular signal-regulated kinase 1/2 (ERK1/2)-mediated phosphorylation. J Biol Chem. 288, 5223–31. doi: 10.1074/jbc.M112.407981 PMID: 23283969